Atomistry » Fluorine » PDB 4x7j-4xxs » 4xv2
Atomistry »
  Fluorine »
    PDB 4x7j-4xxs »
      4xv2 »

Fluorine in PDB 4xv2: B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib

Enzymatic activity of B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib

All present enzymatic activity of B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib:
2.7.11.1;

Protein crystallography data

The structure of B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib, PDB code: 4xv2 was solved by Y.Zhang, C.Zhang, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 54.87 / 2.50
Space group P 21 21 21
Cell size a, b, c (Å), α, β, γ (°) 53.689, 105.666, 109.731, 90.00, 90.00, 90.00
R / Rfree (%) 21.2 / 24.4

Fluorine Binding Sites:

The binding sites of Fluorine atom in the B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib (pdb code 4xv2). This binding sites where shown within 5.0 Angstroms radius around Fluorine atom.
In total 6 binding sites of Fluorine where determined in the B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib, PDB code: 4xv2:
Jump to Fluorine binding site number: 1; 2; 3; 4; 5; 6;

Fluorine binding site 1 out of 6 in 4xv2

Go back to Fluorine Binding Sites List in 4xv2
Fluorine binding site 1 out of 6 in the B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 1 of B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib within 5.0Å range:
probe atom residue distance (Å) B Occ
A:F801

b:37.5
occ:1.00
 F39 A:P06801 0.0 37.5 1.0
C32 A:P06801 1.3 33.9 1.0
C31 A:P06801 2.3 32.5 1.0
C30 A:P06801 2.4 33.5 1.0
N40 A:P06801 2.7 28.4 1.0
C16 A:P06801 2.8 33.3 1.0
N15 A:P06801 2.9 34.3 1.0
O A:HOH913 3.0 31.0 1.0
N A:ASP594 3.1 38.3 1.0
CA A:ASP594 3.4 38.5 1.0
CB A:ASP594 3.4 41.0 1.0
C33 A:P06801 3.6 29.5 1.0
C35 A:P06801 3.6 31.7 1.0
CE2 A:PHE583 3.9 43.4 1.0
C12 A:P06801 3.9 35.1 1.0
C A:GLY593 3.9 37.8 1.0
CZ A:PHE583 3.9 39.2 1.0
OD1 A:ASP594 4.0 50.0 1.0
C14 A:P06801 4.0 37.0 1.0
CG A:ASP594 4.0 49.2 1.0
C37 A:P06801 4.1 27.3 1.0
CA A:GLY593 4.2 38.5 1.0
S42 A:P06801 4.3 33.8 1.0
NZ A:LYS483 4.3 42.6 1.0
CD2 A:LEU514 4.4 30.7 1.0
C22 A:P06801 4.6 38.1 1.0
C4 A:P06801 4.8 36.2 1.0
S13 A:P06801 4.8 39.5 1.0
C2 A:P06801 4.8 36.7 1.0
CE A:LYS483 4.8 41.7 1.0
O A:GLY593 4.8 34.3 1.0
C A:ASP594 4.9 41.4 1.0
O54 A:P06801 4.9 36.3 1.0
O55 A:P06801 4.9 34.5 1.0
C17 A:P06801 5.0 38.8 1.0
OD2 A:ASP594 5.0 52.6 1.0

Fluorine binding site 2 out of 6 in 4xv2

Go back to Fluorine Binding Sites List in 4xv2
Fluorine binding site 2 out of 6 in the B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 2 of B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib within 5.0Å range:
probe atom residue distance (Å) B Occ
A:F801

b:43.3
occ:1.00
 F52 A:P06801 0.0 43.3 1.0
C49 A:P06801 1.3 39.4 1.0
C50 A:P06801 2.4 38.8 1.0
C43 A:P06801 2.4 38.5 1.0
O55 A:P06801 2.7 34.5 1.0
S42 A:P06801 2.9 33.8 1.0
N40 A:P06801 3.1 28.4 1.0
CA A:GLY593 3.1 38.5 1.0
N A:ASP594 3.3 38.3 1.0
C A:GLY593 3.5 37.8 1.0
C47 A:P06801 3.6 38.8 1.0
C46 A:P06801 3.6 37.2 1.0
CE1 A:PHE595 3.6 52.2 1.0
CD1 A:PHE595 3.7 53.2 1.0
CZ A:PHE595 3.9 53.0 1.0
O A:ILE592 4.0 42.4 1.0
CG A:PHE595 4.0 52.9 1.0
C44 A:P06801 4.1 37.8 1.0
N A:PHE595 4.2 42.4 1.0
C31 A:P06801 4.2 32.5 1.0
CE2 A:PHE595 4.3 55.0 1.0
CD2 A:LEU514 4.3 30.7 1.0
CD2 A:PHE595 4.3 55.4 1.0
CB A:LEU514 4.3 31.1 1.0
N A:GLY593 4.3 39.3 1.0
O54 A:P06801 4.3 36.3 1.0
CA A:ASP594 4.4 38.5 1.0
O A:GLY593 4.5 34.3 1.0
C A:ILE592 4.6 38.8 1.0
CD2 A:LEU505 4.7 38.3 1.0
F53 A:P06801 4.8 34.7 1.0
C A:ASP594 4.8 41.4 1.0
CB A:PHE595 4.8 48.9 1.0
CG A:LEU514 4.9 31.1 1.0
C33 A:P06801 4.9 29.5 1.0

Fluorine binding site 3 out of 6 in 4xv2

Go back to Fluorine Binding Sites List in 4xv2
Fluorine binding site 3 out of 6 in the B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 3 of B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib within 5.0Å range:
probe atom residue distance (Å) B Occ
A:F801

b:34.7
occ:1.00
 F53 A:P06801 0.0 34.7 1.0
C46 A:P06801 1.3 37.2 1.0
C44 A:P06801 2.3 37.8 1.0
C43 A:P06801 2.4 38.5 1.0
O54 A:P06801 2.7 36.3 1.0
S42 A:P06801 3.1 33.8 1.0
CG2 A:ILE527 3.1 38.9 1.0
CD1 A:LEU505 3.3 44.1 1.0
C33 A:P06801 3.5 29.5 1.0
C47 A:P06801 3.6 38.8 1.0
C49 A:P06801 3.6 39.4 1.0
CG2 A:THR529 3.6 28.1 1.0
CB A:ILE527 4.1 37.6 1.0
C50 A:P06801 4.1 38.8 1.0
N40 A:P06801 4.2 28.4 1.0
CD1 A:ILE527 4.2 39.9 1.0
O55 A:P06801 4.2 34.5 1.0
C31 A:P06801 4.3 32.5 1.0
CG A:LEU505 4.4 42.5 1.0
CD2 A:LEU505 4.4 38.3 1.0
C37 A:P06801 4.5 27.3 1.0
CG1 A:ILE527 4.7 39.6 1.0
F52 A:P06801 4.8 43.3 1.0
CB A:LEU505 5.0 41.3 1.0

Fluorine binding site 4 out of 6 in 4xv2

Go back to Fluorine Binding Sites List in 4xv2
Fluorine binding site 4 out of 6 in the B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 4 of B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib within 5.0Å range:
probe atom residue distance (Å) B Occ
B:F801

b:44.6
occ:1.00
 F39 B:P06801 0.0 44.6 1.0
C32 B:P06801 1.3 43.4 1.0
C31 B:P06801 2.3 42.6 1.0
C30 B:P06801 2.4 42.7 1.0
N40 B:P06801 2.7 40.8 1.0
C16 B:P06801 2.8 44.1 1.0
O B:HOH913 2.8 49.0 1.0
N15 B:P06801 2.9 46.9 1.0
N B:ASP594 3.1 43.8 1.0
CB B:ASP594 3.4 46.0 1.0
CA B:ASP594 3.4 45.1 1.0
C33 B:P06801 3.6 42.2 1.0
C35 B:P06801 3.6 42.7 1.0
CZ B:PHE583 3.8 51.9 1.0
C12 B:P06801 3.8 44.5 1.0
C14 B:P06801 3.9 48.2 1.0
C B:GLY593 4.0 38.9 1.0
CE2 B:PHE583 4.0 51.1 1.0
C37 B:P06801 4.1 41.8 1.0
CG B:ASP594 4.1 50.3 1.0
NZ B:LYS483 4.1 49.4 1.0
CA B:GLY593 4.3 32.4 1.0
OD1 B:ASP594 4.3 51.5 1.0
S42 B:P06801 4.3 46.3 1.0
CD2 B:LEU514 4.4 34.0 1.0
C26 B:P06801 4.7 44.7 1.0
C2 B:P06801 4.7 45.8 1.0
CE B:LYS483 4.7 50.7 1.0
S13 B:P06801 4.7 48.1 1.0
C4 B:P06801 4.7 43.9 1.0
O55 B:P06801 4.9 47.1 1.0
O54 B:P06801 4.9 44.8 1.0
C17 B:P06801 4.9 47.9 1.0
O B:GLY593 4.9 38.6 1.0
C B:ASP594 4.9 47.8 1.0
OD2 B:ASP594 5.0 53.5 1.0
CE1 B:PHE583 5.0 51.9 1.0

Fluorine binding site 5 out of 6 in 4xv2

Go back to Fluorine Binding Sites List in 4xv2
Fluorine binding site 5 out of 6 in the B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 5 of B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib within 5.0Å range:
probe atom residue distance (Å) B Occ
B:F801

b:50.0
occ:1.00
 F52 B:P06801 0.0 50.0 1.0
C49 B:P06801 1.3 48.3 1.0
C50 B:P06801 2.4 48.3 1.0
C43 B:P06801 2.4 47.5 1.0
O55 B:P06801 2.8 47.1 1.0
S42 B:P06801 3.0 46.3 1.0
CA B:GLY593 3.1 32.4 1.0
N40 B:P06801 3.2 40.8 1.0
N B:ASP594 3.4 43.8 1.0
CE1 B:PHE595 3.5 66.3 1.0
C B:GLY593 3.6 38.9 1.0
C47 B:P06801 3.6 47.7 1.0
C46 B:P06801 3.6 47.2 1.0
CD1 B:PHE595 3.7 66.5 1.0
CZ B:PHE595 3.8 65.9 1.0
O B:ILE592 3.9 32.6 1.0
CD2 B:LEU514 4.0 34.0 1.0
CG B:PHE595 4.1 64.7 1.0
C44 B:P06801 4.1 47.4 1.0
CB B:LEU514 4.2 35.3 1.0
CE2 B:PHE595 4.2 67.3 1.0
N B:GLY593 4.3 33.0 1.0
CD2 B:PHE595 4.3 67.0 1.0
C31 B:P06801 4.3 42.6 1.0
N B:PHE595 4.4 49.6 1.0
O54 B:P06801 4.4 44.8 1.0
CD2 B:LEU505 4.5 47.9 1.0
C B:ILE592 4.5 33.4 1.0
O B:GLY593 4.5 38.6 1.0
CA B:ASP594 4.5 45.1 1.0
CG B:LEU514 4.7 37.1 1.0
F53 B:P06801 4.8 48.5 1.0
C B:ASP594 4.9 47.8 1.0
C33 B:P06801 5.0 42.2 1.0
CB B:PHE595 5.0 60.5 1.0
O B:LEU514 5.0 38.1 1.0

Fluorine binding site 6 out of 6 in 4xv2

Go back to Fluorine Binding Sites List in 4xv2
Fluorine binding site 6 out of 6 in the B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 6 of B-Raf Kinase V600E Oncogenic Mutant in Complex with Dabrafenib within 5.0Å range:
probe atom residue distance (Å) B Occ
B:F801

b:48.5
occ:1.00
 F53 B:P06801 0.0 48.5 1.0
C46 B:P06801 1.3 47.2 1.0
C44 B:P06801 2.3 47.4 1.0
C43 B:P06801 2.4 47.5 1.0
O54 B:P06801 2.6 44.8 1.0
S42 B:P06801 3.0 46.3 1.0
CG2 B:ILE527 3.2 42.2 1.0
CD1 B:LEU505 3.3 51.1 1.0
C33 B:P06801 3.5 42.2 1.0
CG2 B:THR529 3.6 43.1 1.0
C47 B:P06801 3.6 47.7 1.0
C49 B:P06801 3.6 48.3 1.0
CB B:ILE527 4.0 47.1 1.0
N40 B:P06801 4.1 40.8 1.0
C50 B:P06801 4.1 48.3 1.0
O55 B:P06801 4.2 47.1 1.0
C31 B:P06801 4.2 42.6 1.0
CD1 B:ILE527 4.2 46.1 1.0
CD2 B:LEU505 4.3 47.9 1.0
CG B:LEU505 4.4 50.8 1.0
C37 B:P06801 4.5 41.8 1.0
CG1 B:ILE527 4.7 47.4 1.0
F52 B:P06801 4.8 50.0 1.0

Reference:

C.Zhang, W.Spevak, Y.Zhang, E.A.Burton, Y.Ma, G.Habets, J.Zhang, J.Lin, T.Ewing, B.Matusow, G.Tsang, A.Marimuthu, H.Cho, G.Wu, W.Wang, D.Fong, H.Nguyen, S.Shi, P.Womack, M.Nespi, R.Shellooe, H.Carias, B.Powell, E.Light, L.Sanftner, J.Walters, J.Tsai, B.L.West, G.Visor, H.Rezaei, P.S.Lin, K.Nolop, P.N.Ibrahim, P.Hirth, G.Bollag. Raf Inhibitors That Evade Paradoxical Mapk Pathway Activation. Nature V. 526 583 2015.
ISSN: ESSN 1476-4687
PubMed: 26466569
DOI: 10.1038/NATURE14982
Page generated: Thu Aug 1 06:48:33 2024

Last articles

Zn in 9JYW
Zn in 9IR4
Zn in 9IR3
Zn in 9GMX
Zn in 9GMW
Zn in 9JEJ
Zn in 9ERF
Zn in 9ERE
Zn in 9EGV
Zn in 9EGW
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy